Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Project Name | Modality | Therapeutic Area | Indications | Stage | Right Available |
| GIP/GLP-1/FGF21 Fusion Protein treating NASH, T2DM, Hyperlipoidemia | NASH, T2DM, Hyperlipoidemia | Preclinical |
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| FG1-H82Q3 | Human | Biotinylated Human FGF-21 Protein, His,Avitag™ |  |
|
|
| FG1-H5243 | Human | Human FGF-21 Protein, His Tag |  |
|
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Pegozafermin | BIO89-100; TEV-47948 | Phase 2 Clinical | 89bio Inc, Teva | Hypertriglyceridemia; Non-alcoholic Fatty Liver Disease | Details |
| BOS-580 | Phase 2 Clinical | Novartis Pharma Ag | Non-alcoholic Fatty Liver Disease | Details | |
| HEC-88473 | HEC-88473 | Phase 1 Clinical | Dongguan City Hec Biological Medicine Res And Development Co Ltd | Non-alcoholic Fatty Liver Disease; Diabetes Mellitus, Type 2; Obesity | Details |
| Recombinant human FGF21 Fc fusion protein(Anyuan Pharmaceutical) | AP-025 | Phase 1 Clinical | Anyuan Pharmaceutical Technology (Shanghai) Co Ltd | Non-alcoholic Fatty Liver Disease | Details |
| AP-026 | AP-026 | Phase 1 Clinical | Anyuan Pharmaceutical Technology (Shanghai) Co Ltd | Non-alcoholic Fatty Liver Disease | Details |
This web search service is supported by Google Inc.
A-Z
